Anticorps VEGF-C (30AT1174.77.260): sc-130289
- L'anticorps VEGF-C 30AT1174.77.260 est un monoclonal IgG1 de souris, cité dans 2 publications, fourni en 100 µg/ml
- dirigé contre des peptides en N-terminal, interne et C-terminal de VEGF-C de human
- recommandé pour la détection de VEGF-C d'origine mouse, rat et human par WB, IP et ELISA
- Voir VEGF-C (E-6): sc-374628 pour d'autres anticorps conjugués VEGF-C, dont AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 et 790.
- Nous testons actuellement encore nos anticorps secondaires pour trouver la meilleure protéine de liaison pour cet anticorps primaire VEGF-C (30AT1174.77.260). Veuillez nous contacter si vous avez des questions concernant les réactifs de détection secondaire appropriés.
The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor in vivo. Two additional proteins, designated VEGF-B and VEGF-C, share a significant degree of homology with VEGF. VEGF-B is abundantly expressed in heart and skeletal muscle and is frequently coexpressed with VEGF. VEGF-C binds to and specifically activates Flt-4 and Flk-1. The genes that encode VEGF-B and VEGF-C have been localized to chromosomes 11q13.1 and 4q34.3, respectively.
Informations pour la commande
| Nom du produit | Ref. Catalogue | COND. | Prix HT | QTÉ | Favoris | |
Anticorps VEGF-C (30AT1174.77.260) | sc-130289 | 100 µg/ml | $316.00 |